▶ EPITALON · SUBTOPIC · DOSING LITERATURE

EPITALON Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of EPITALON. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for EPITALON reports the following route(s) of administration: Subcutaneous (Russian research protocol), Intranasal (some sources). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of EPITALON.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for EPITALON of approximately Very short (minutes) plasma; tissue-localized longer. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of EPITALON. Refer to the original publication for full protocol detail.

Khavinson VKh (2002) reports the EPITALON protocol used in Peptides and Ageing, published in Neuro Endocrinol Lett. PMID 12624353. See the source for the protocol-level dose range, frequency, and duration. link
Khavinson V, et al. (2003) reports the EPITALON protocol used in Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and animals, published in Neuro Endocrinol Lett. PMID 14523389. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What dose is used in research?

Russian-protocol literature uses subcutaneous 5-10 mg/day in 10-20 day cycles, 1-2 times per year. This wiki does not recommend any human dose.

▶ Side effects?

Very limited Western safety data. No serious adverse events reported in Russian literature at standard doses; appropriate caution warranted given the limited Western RCT base.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · -20 °C 24 months

Reconstituted · 2-8 °C, 14-21 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only in the United States.

WADA · Not currently listed on the WADA Prohibited List.

◀ EPITALON OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19